VCs are often betting that their portfolio companies will disrupt lives. But those who bet on biopharma are counting on innovations that save lives. Since investment in biopharma peaked in 2021, VCs have been more discerning with their capital, keeping a closer eye on clinical trial results and making late-stage deals. PitchBook’s inaugural biopharma Emerging Tech Research report offers a comprehensive primer and an update on VC trends in the sector. PitchBook’s biopharma analyst spotlights traditional investment areas like chemistry and biologics, as well as cutting-edge spaces like gene therapy and cell therapy, among others.
Read the full article: PitchBook Q3 2023 Launch Report: Biopharma //